-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Downgrades Day One Biopharmaceutical to Neutral, Lowers Price Target to $21.5

Benzinga·03/09/2026 12:35:01
Listen to the news
Wedbush analyst Robert Driscoll downgrades Day One Biopharmaceutical (NASDAQ:DAWN) from Outperform to Neutral and lowers the price target from $30 to $21.5.